Skip to main content

Table 1 Baseline characteristics

From: Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort

Characteristic

 

Freq. (%)

Dose-dense regimen

(n = 69)

Conventional regimen

(n = 138)

pa

Age

 Median (P25–75)

52.6 (45.5–59.1)

54.8 (47.3–61.3)

0.290

 ≤ 65

64 (92.8)

128 (92.8)

1.000

 > 65

5 (7.2)

10 (7.2)

 

FIGO stage

 I -II

5 (7.2)

10 (7.2)

1.000

 III-IV

64 (92.8)

128 (92.8)

 

Histology

 High-grade serous carcinoma

61 (88.4)

111 (80.4)

0.149

 Others

8 (11.6)

27 (19.6)

 

ECOG performance status

 0

45 (65.2)

79 (57.2)

0.134

 ≥ 1

21 (30.4)

59 (42.8)

 

 Missing data

3 (4.3)

0 (0)

 

CA125

 Median (P25–75)

344 (72.8–1427)

392.8 (97–1470.2)

0.614

 ≤ 200

29 (42)

52 (37.7)

0.442

 > 200

38 (55.1)

86 (62.3)

 

 Missing data

2 (2.9)

0 (0)

 

Type of cytoreductive surgery

 Primary

48 (69.6)

92 (66.7)

0.674

 Interval

21 (30.4)

46 (33.3)

 

Complete cytoreduction

 Yes

61 (88.4)

120 (87)

0.570

 No

7 (10.1)

18 (13)

 

 Missing data

1 (1.4)

0 (0)

 

BRCA1/2 mutation

 Yes

14 (20.3)

11 (8)

0.793

 No

44 (63.9)

39 (28.2)

 

 Missing data

11 (15.9)

88 (63.8)

 

Family history of breast or ovarian cancer

 Yes

21 (30.4)

46 (33.4)

0.778

 No

43 (62.4)

86 (62.3)

 

 Missing data

5 (7.2)

6 (4.3)

 
  1. aUsed to compare valid data only. All p values calculated by chi square test